Results 131 to 140 of about 1,997 (174)

Familial hypercholesterolaemia in children and adolescents: a European Atherosclerosis Society consensus statement. [PDF]

Eur Heart J
Wiegman A, Bourbon M, Freiberger T, Gidding SS, Greber-Platzer S, Groselj U, Holven KB, Hudgins LC, Humphries SE, Hutten BA, Ibarretxe D, Pederiva C, Peretti N, Raal FJ, Ramaswami U, Sanin V, Santos RD, Steinhagen-Thiessen E, Watts GF, Perkins R, Benn M, Binder CJ, Romeo S, Roeters van Lennep JE.   +23 more
europepmc   +1 more source

Correction: Suriya et al. Integration of In Silico Strategies for Drug Repositioning towards P38α Mitogen-Activated Protein Kinase (MAPK) at the Allosteric Site. <i>Pharmaceutics</i> 2022, <i>14</i>, 1461. [PDF]

Pharmaceutics
Suriya U, Mahalapbutr P, Rungrotmongkol T.   +2 more
europepmc   +1 more source

Homozygous Familial Hypercholesterolemia Treatment: New Developments. [PDF]

Curr Atheroscler Rep
Blom DJ, Marais AD, Raal FJ.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Targeting PARP14 with lomitapide suppresses drug resistance through the activation of DRP1-induced mitophagy in multiple myeloma

Cancer Letters
Multiple myeloma (MM) is a hematological malignancy that remains incurable, primarily due to the high likelihood of relapse or development of resistance to current treatments.
Yuhua Li, Yingqi Qiu, Yuxing Hu
exaly   +2 more sources

Long-term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia [PDF]

Liver International, 2023
Introduction: Lomitapide is a microsomal triglyceride transfer protein inhibitor for patients with homozygous familial hypercholesterolaemia. Due to its mechanism of action, potential hepatic effects of lomitapide are of clinical interest.
Iannuzzo Gabriella, Laura D'Erasmo, Marcello Arca   +2 more
exaly   +4 more sources

Efficacy and safety of lomitapide in familial chylomicronaemia syndrome [PDF]

Atherosclerosis, 2022
Background and aims Familial chylomicronaemia syndrome (FCS) is a rare autosomal recessive disorder, resulting in elevated triglycerides (TGs), abdominal pain and pancreatitis. Treatment options are limited.
Alberto Zambon, Antonina Giammanco, Patrizia Suppressa   +2 more
exaly   +2 more sources

Lomitapide affects HDL composition and function [PDF]

Atherosclerosis, 2016
Background: Lomitapide reduces low-density lipoprotein-cholesterol (LDL-C) but also high-density lipoprotein-cholesterol (HDL-C) levels. The latter may reduce the clinical efficacy of lomitapide.
Eric Sijbrands, Elda Favari, Maurizio Averna   +2 more
exaly   +2 more sources